About Saxenda Injectable Pens
(See the Original Document Here)
What is Type 2 diabetes? When a person has type 2 diabetes, body cells become resistant to insulin. As a result, your body makes more insulin to get cells to respond. This imbalance in your blood sugar may lead to type 2 diabetes. High blood sugar can cause serious health problems, causing amputation or affecting your heart, vision, and kidneys.
What is Type 1 diabetes? Type 1 diabetes is an immune system disorder in which the body cannot make insulin or produces insulin in a tiny amount.
Saxenda Injectable Pens contain liraglutide, an analog of human insulin. This type of insulin uses DNA technology in Saccharomyces cerevisiae. GLP-1 acts as a GLP-1 receptor agonist. The peptide precursor of liraglutide, produced by a process that includes the expression of recombinant DNA in Saccharomyces cerevisiae, is engineered to be 97% homologous to native human GLP-1. It is a clear, colorless solution. Each 1 mL of SAXENDA solution contains 6 mg of liraglutide. Each pre-filled pen of 3 mL solution contains a total of 18 mg of liraglutide (free-base, anhydrous). Liraglutide is a long-acting Glucagon-like Peptide-1 (GLP-1) receptor agonist. Liraglutide inside Saxenda injectable pens is a long-acting GLP-1 receptor agonist. It will release more insulin in the blood as the blood glucose increases, and insulin release decreases as the demand for insulin in the body reduces.
The glucagon-like peptide-1 (GLP-1) receptor works in three ways to control blood glucose.
- It helps the body produce more insulin.
- It helps slow down the liver’s release of sugar into the bloodstream.
- It slows the rate at which food leaves your stomach and passes into the intestine.
Warning while using Saxenda Injectable Pens
For Saxenda Injectable Pens 6 mg/m, some risks associated with this type of medicine are listed below:
- Risk of Thyroid C-Cell Tumors
- Breast neoplasms
- Cardiovascular
- Endocrine and metabolic
- Hypoglycemia
- Hepatic/Biliary/Pancreatic
- Acute Gallbladder Disease
- Immune
- Hypersensitivity Reactions
- Psychiatric
- Suicidal Behavior and Ideation
Other precautions while using Saxenda injectable pens
- Pregnant women: Do not use SAXENDA during pregnancy.
- Breastfeeding: women who are nursing.
- You should discontinue SAXENDA treatment.
- Pediatrics: can be used for children between 12 and 18 years old.
- Geriatrics: Patients over 65 years old may experience gastrointestinal side effects.
- Cardiovascular: SAXENDA should be used cautiously in patients with recent myocardial infarction, unstable angina, and congestive heart failure.
- Hepatic Insufficiency: SAXENDA is not recommended.
- Renal Insufficiency: Use caution when initiating or escalating doses of Saxenda.
Gastrointestinal disorders may include:
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Dyspepsia
- Abdominal Pain
- Abdominal Pain Upper
- Abdominal distension
- Eructation
- Flatulence
- Gastroesophageal reflux disease
- Dry Mouth
- Gastritis
The symptoms of hypoglycemia may include:
- Dizziness or lightheartedness
- blurred vision
- anxiety, irritability, or mood changes
- sweating
- slurred speech
- hunger
- confusion or drowsiness.
- shakiness
- weakness
- headache
- fast heartbeat
- feeling jittery
What is the dosage for Saxenda injectable pens?
- Do not use Saxenda and Victoza together, as they have a common ingredient.
- Saxenda and Victoza are not substitutes for each other.
- Do not take SAXENDA with another insulin.
- For patients with type 2 diabetes mellitus, do not combine SAXENDA with another GLP-1 receptor agonist.
- SAXENDA is not a replacement for insulin.
- If you discontinue SAXENDA in patients with type 2, you may notice an increase in blood glucose.
In adults with an initial BMI of 27 kg/m2 or greater, the recommended daily maintenance dose is 3.0 mg/day. We do not recommend daily doses higher than 3.0 mg.
How do I store Saxenda injectable pens?
Store Saxenda injectable pens in a refrigerator (2ºC to 8ºC). Do not store in the freezer or next to the refrigerator cooling element. Avoid freezing SAXENDA®, and refrain from using it once it has frozen. After initial use of the Saxenda Injectable Pens, the product can be stored for 30 days at room temperature (not above 30°C) or in a refrigerator (2°C to 8°C).
Unused: Store in a refrigerator (2ºC to 8ºC). Do not freeze. Discard Saxenda injectable pens if they are frozen.
Used: Until expiry or a maximum of 30 days at room temperature (not above 30°C) or in a refrigerator (2°C to 8°C).
